Skip to main content
logo
Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
14.89
+0.06 (0.40%)
At close: Oct 21, 2026, 4:00 PM EDT
15.09
+0.20 (1.34%)
Pre-market: Oct 22, 2026, 7:35 AM EDT

Cullinan Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
-----18.94
Revenue Growth
------
Gross Profit
-----18.94
Operating Income
-221.81-241.65-196.92-190.65-132.14-67.95
Net Income
-208.34-219.88-167.38-153.16111.21-65.57
Earnings Per Share
-3.47-3.72-3.11-3.692.38-1.52
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
334.54377.9398.98467.07467.29290.47
Total Debt
2.072.682.153.595.19-
Net Cash (Debt)
332.47375.21396.83463.48462.1290.47
Net Cash Growth
25.95%-5.45%-14.38%0.30%59.09%38.18%
Net Cash Per Share
5.546.357.3811.159.916.74

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-159.25-175.75-145.3-134.28-126.66-43.43
Capital Expenditures
-0.05-0.05--0.21-1.13-
Free Cash Flow
-159.3-175.8-145.3-134.48-127.8-43.43
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-----100.00%
Operating Margin
------358.73%
Pretax Margin
------356.25%
Profit Margin
------346.14%
FCF Margin
------229.28%

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
----4.34-
Forward PE
-6.706.706.706.70-
PS Ratio
-----35.58